Target |
Gene |
Vector/Delivery |
Immunization |
Response |
Reference |
Brain tumor |
IL-12 |
SFV / Particles |
Mouse |
Immunogenicity |
[93] |
Cervical cancer |
HPVE6-E7 |
SFV / Particles |
Mouse |
Tumor protection |
[94] |
Glioma |
B16, 203 |
SFV / Particles |
Mouse |
Tumor protection |
[95] |
Melanoma |
MDA/trp-2 |
VEE / Particles |
Mouse |
Therapeutic effect |
[42] |
Tumor |
β-galactosidase |
SFV / RNA |
Mouse |
Tumor protection |
[38] |
Tumor |
HPVE7 |
VEE / Particles |
Mouse |
Tumor protection |
[40] |
Tumor |
HPVE6E7+IL12 |
SFV / Particles |
Mouse |
Anti-tumor activity |
[41] |
Tumor |
HPVE7-VP22 |
SIN / Particles |
Mouse |
CD8+ T-cell response |
[96] |
Tumor |
IL-12 |
SFV / Particles |
Mouse |
Tumor protection |
[97] |
Tumor antigen |
MHC class II |
SFV / Particles-DNA |
Mouse |
Immunogenicity |
[98] |
Tumor antigen |
P185 |
SFV / Particles |
Mouse |
CTL, tumor protection |
[39] |
Tumor antigen |
trp-1 |
SIN / DNA |
Mouse |
Antitumor activity |
[99] |
CTL: Cytotoxic T-lymphocyte activity; HPV: Human papillomavirus; IL: interleukin; MDA: Melanoma differentiation antigen; MHC: Major histocompatibility complex; SFV: Semliki Forest virus; SIN: Sindbis virus; trp: tyrosine-related protein; VEE: Venezuelan equine encephalitis virus |
